Actively Recruiting
Biomarker Guided Treatment in Gynaecological Cancer
Led by Haukeland University Hospital · Updated on 2017-03-28
1300
Participants Needed
9
Research Sites
948 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series. Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers. Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.
CONDITIONS
Official Title
Biomarker Guided Treatment in Gynaecological Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients referred to a participating research center with suspected or confirmed endometrial cancer
- Patients with endometrial or epithelial ovarian cancer who are offered weekly taxane (paclitaxel) treatment following routine clinical guidelines
- Ability to obtain a new tissue biopsy for stathmin level analysis in tumor recurrence
- Female patients aged 18 to 95 years
You will not qualify if you...
- Patients without endometrial cancer (for part 1) or without endometrial or epithelial ovarian cancer (for part 2)
- Patients under 18 years of age
- Patients who cannot or do not give informed consent, including due to language barriers
- Patients who will not undergo surgical treatment for their endometrial cancer
- Patients who do not agree to the proposed treatment or will receive treatment in a non-participating center
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Radboud university hospital
Nijmegen, Netherlands
Not Yet Recruiting
2
Women's hospital, Haukeland university hospital
Bergen, Hordaland, Norway, 5053
Actively Recruiting
3
Ålesund hospital
Ålesund, Norway, 6017
Actively Recruiting
4
Førde central hospital
Førde, Norway, 6812
Actively Recruiting
5
Sørlandet hospital
Kristiansand, Norway, 4604
Not Yet Recruiting
6
Akershus University hospital
Oslo, Norway
Actively Recruiting
7
Stavanger university hospital
Stavanger, Norway, 4011
Actively Recruiting
8
St Olav university hospital
Trondheim, Norway, 7006
Actively Recruiting
9
Spsk No 1
Lublin, Poland, 20-081
Actively Recruiting
Research Team
J
Jone Trovik, MD PhD Prof
CONTACT
H
Henrica MJ Werner, MD PhD MRCOG
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here